融券方面，尔康制药12月29日融券偿还0.00股，融券卖出200.00股，按当日收盘价计算，卖出金额 694.00元；融券余量10.50万股，融券余额36.44万元，低于近一年40%分位水平，处于较低位。 12月29日，尔康制药跌2.53%，成交额1.20亿元。两融数据显示，当日尔康制药获融资买入额1391.12万 元，融资偿还1253.99万元，融资净买入137.13万元。截至12月29日，尔康制药融资融券余额合计2.77亿 元。 融资方面，尔康制药当日融资买入1391.12万元。当前融资余额2.77亿元，占流通市值的3.86%，融资余 额超过近一年80%分位水平，处于高位。 资料显示，湖南尔康制药股份有限公司位于湖南省长沙市浏阳经济开发区北园开元大道工业路1号，成 立日期2003年10月22日，上市日期2011年9月27日，公司主营业务涉及从事医药产品的研发、生产和销 售,主要业务包括药用辅料及新型抗生素产品。主营业务收入构成为：药用辅料36.29%，新能源材料 18.64%，复合辅料16.21%，大宗辅料14.62%，原料药6.88%，成品药5.71%，其他1.64%。 截至9月30日，尔康制药股东户数 ...

天眼查App显示，近日，亳州市利泰盛食品有限公司成立，法定代表人为张杰，注册资本10万人民币， 经营范围为一般经营项目：食品销售（仅销售预包装食品）；保健食品（预包装）销售；食品添加剂销 售；食品互联网销售（仅销售预包装食品）；农副产品销售；普通货物仓储服务（不含危险化学品等需 许可审批的项目）（除许可业务外，可自主依法经营法律法规非禁止或限制的项目）许可经营项目：食 品销售；药用辅料销售（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以 相关部门批准文件或许可证件为准）。 ...

目前国内医药生产企业众多，竞争较为激烈，昂利康始终坚持将研发作为企业的核心发展动力，注重业 内合作，立足于开发具有临床价值的优质产品。经过多年的发展，在口服头孢类抗生素原料药、alpha 酮酸原料药、心血管类制剂、吸入用麻醉原料药、抗雄性激素中间体及植物源胆固醇系列产品上均具有 显著优势。公司是国内最早掌握酶法技术的口服头孢类原料药生产厂家之一；公司是国内最大的alpha 酮酸原料药生产厂家，也是费森尤斯卡比的核心原料药供应商之一；公司是国内钙拮抗剂类抗高血压制 剂的主要生产企业之一，苯磺酸左氨氯地平片在国内市场具有较高的市场占有率；公司是国内主要的吸 入用麻醉原料药和制剂一体化的生产企业；公司是国内较早以植物甾醇生物发酵所得产品为起始原料生 产甾体药物中间体的企业，是国内首家实现植物源胆固醇规模化生产的企业，在抗雄性激素中间体、植 物源胆固醇、植物源维生素D系列等细分领域已取得行业领先地位。 此次入选两项榜单，既是对昂利康创新工作的肯定，也将激励企业继续前进。未来，昂利康将继续坚持 研发投入，加强专利布局，推动更多优质医药产品上市，为浙江省民营经济高质量发展贡献力量，助力 公众健康事业发展。 昂利康主要从事 ...

Core Viewpoint - Shanxi Guangyuyuan Pharmaceutical Technology Co., Ltd. has recently been established with a registered capital of 50 million yuan, indicating a strategic expansion in the pharmaceutical sector by Guangyuyuan [1] Company Summary - The newly established company is fully owned by Guangyuyuan, reflecting its commitment to diversifying its business operations [1] - The business scope includes drug wholesale, retail, sales of medicinal auxiliary materials, food sales, traditional Chinese medicine decoction services, and internet information services related to pharmaceuticals [1]

Group 1 - The company Jiutian Pharmaceutical (SZ 300705) announced that its 15th meeting of the 4th board of directors was held on November 17, 2025, to review documents including proposals for external investments [1] - For the first half of 2025, Jiutian Pharmaceutical's revenue composition was as follows: 82.47% from pharmaceutical preparations, 7.65% from raw materials, 6.03% from pharmaceutical excipients, 3.16% from plant extracts and others, and 0.63% from technology transfer and services [1] - As of the report date, Jiutian Pharmaceutical's market capitalization was 8.4 billion yuan [1]

Group 1 - The core viewpoint of the article highlights the strategic partnership between Clariant and Fuhua to establish a joint venture focused on developing innovative halogen-free flame retardants, addressing the increasing regulatory challenges in various industries such as construction, automotive, and electronics [2][3] - Clariant's proactive strategy allows the company to anticipate regulatory changes and develop compliant alternatives, effectively supplementing the production capacity of its Exolit™OP plants in Germany [3] - The announcement of the partnership coincides with the launch of a second production line for high-performance halogen-free flame retardants at Clariant's Daya Bay facility, which represents an investment of approximately 100 million Swiss francs [5] Group 2 - The expansion at the Daya Bay facility not only focuses on flame retardants but also enhances production capabilities in pharmaceutical excipients and specialty chemicals for personal and home care, thereby meeting consumer demand for high-quality products [5] - In the industrial and agricultural sectors, Clariant has developed low VOC emission water-based coatings and synthetic lubricants, as well as crop protection additives aimed at improving soil health and efficiency [6] - The new production line for Nylostab™S-EED stabilizers in Cangzhou enhances the capacity for two core products that are crucial for the nylon industry, improving processing stability and product quality [6][7]

Core Insights - Warner Pharmaceutical reported a revenue of approximately 1.086 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.55% [1] - The net profit attributable to shareholders reached about 207 million yuan, marking a significant year-on-year increase of 30.75% [1] - Basic earnings per share were 1.58 yuan, also reflecting a year-on-year increase of 30.58% [1] Financial Performance - Total assets of Warner Pharmaceutical increased to approximately 2.781 billion yuan, a growth of 13.06% compared to the end of the previous year [1] - Revenue composition for the first three quarters included approximately 805 million yuan from formulation products, 262 million yuan from raw materials and intermediates, and 12 million yuan from technical services [1] Company Overview - Established in 2001, Warner Pharmaceutical specializes in the R&D, production, and sales of chemical raw materials, chemical drugs, and traditional Chinese medicine formulations [1] - The company has developed into a key member of Hunan's biopharmaceutical industry chain, with 71 specialty chemical raw material varieties and 59 registered chemical drug formulation approvals [1] R&D Investment - Warner Pharmaceutical has increased its R&D investment to 106 million yuan in the first three quarters of this year, accounting for 9.75% of its operating revenue [2] - The company was recognized in the TOP 100 of the "2025 China Chemical Drug R&D Strength Ranking" at the 2025 PDI Pharmaceutical R&D Innovation Conference [2]

Core Viewpoint - 威尔药业 is a significant player in the pharmaceutical excipients and synthetic lubricants sector in China, showcasing strong R&D capabilities and product quality advantages. Group 1: Company Overview - 威尔药业 was established on February 18, 2000, and was listed on the Shanghai Stock Exchange on January 30, 2019, with its registered and office locations in Nanjing, Jiangsu Province [1]. - The company primarily engages in the R&D, production, and sales of pharmaceutical excipients and synthetic lubricants, classified under the pharmaceutical and biological industry [1]. Group 2: Financial Performance - In Q3 2025, 威尔药业 reported a revenue of 1.018 billion yuan, ranking 17th among 47 companies in the industry, with the industry leader, 普洛药业, generating 7.764 billion yuan [2]. - The net profit for the same period was 112 million yuan, placing 威尔药业 at 16th in the industry, while the top performer, 浙江医药, achieved a net profit of 867 million yuan [2]. Group 3: Financial Ratios - As of Q3 2025, 威尔药业's debt-to-asset ratio was 31.69%, an increase from 26.48% year-on-year, and above the industry average of 27.75% [3]. - The gross profit margin for Q3 2025 was 28.48%, up from 25.93% year-on-year, but still below the industry average of 35.38% [3]. Group 4: Executive Compensation - The chairman, 吴仁荣, received a salary of 1.0133 million yuan in 2024, reflecting an increase of 22,600 yuan from 2023 [4]. Group 5: Shareholder Information - As of September 30, 2025, 威尔药业 had 6,776 A-share shareholders, a 5.36% increase from the previous period, with an average of 20,000 circulating A-shares held per shareholder, down by 5.09% [5]. - The company is focusing on dual growth drivers from synthetic lubricants and pharmaceutical excipients, with strategic initiatives in high-tech sectors and high-value new products [5].

Core Viewpoint - Erkang Pharmaceutical is a leading enterprise in the pharmaceutical excipients industry in China, with a comprehensive industry chain advantage and strong product quality and market share [1] Group 1: Business Performance - In Q3 2025, Erkang Pharmaceutical reported a revenue of 1.006 billion yuan, ranking 18th among 47 companies in the industry, significantly lower than the top company, Puluo Pharmaceutical, which had a revenue of 7.764 billion yuan [2] - The main business composition includes pharmaceutical excipients, which accounted for 246 million yuan, representing 36.29% of total revenue [2] - The net profit for the same period was 27.11 million yuan, ranking 32nd in the industry, and was substantially lower than the leading company, Zhejiang Pharmaceutical, which reported a net profit of 867 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the debt-to-asset ratio for Erkang Pharmaceutical was 15.20%, an increase from 12.90% in the previous year, and lower than the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 27.37%, down from 30.94% year-on-year, and below the industry average of 35.38%, suggesting a need for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 14.88% to 49,100, while the average number of circulating A-shares held per shareholder decreased by 12.95% to 29,000 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the fifth largest, holding 25.8786 million shares, an increase of 4.3188 million shares from the previous period [5] Group 4: Executive Compensation - The chairman, Shuai Fangwen, received a salary of 512,900 yuan in 2024, a slight increase from 512,600 yuan in 2023 [4] - The general manager, Sun Qingrong, saw a significant salary increase to 1.0148 million yuan in 2024 from 335,700 yuan in 2023, reflecting a rise of 679,100 yuan [4]

证券代码：603351 证券简称：威尔药业 公告编号：2025-032 （一）主要产品销售价格变动情况 单位：元/吨（不含税） | 主要产品 | 2025 年 1-9 月 平均售价 | 2024 年 1-9 月 平均售价 | 变动比例 | | --- | --- | --- | --- | | 1、合成润滑基础油 | 14,838.44 | 15,734.98 | -5.70% | | 其中：机械类 | 16,267.41 | 17,859.70 | -8.92% | | 非机械类 | 11,454.28 | 11,718.61 | -2.26% | | 2、药用辅料 | 27,215.59 | 31,477.51 | -13.54% | | 其中：注射用 | 249,791.39 | 273,647.23 | -8.72% | | 非注射用 | 19,776.42 | 20,158.03 | -1.89% | （二）主要原材料价格波动情况 南京威尔药业集团股份有限公司 关于公司2025年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的 ...